Evidence map›Paper›PMID 38018214›Full record

ReviewRecent patents on nanotechnology2025

Emerging Treatment Options of Pluronic in Designing Colloidal Nano and Micro Carriers for Various Therapies.

Pooja Mathur, Ravinder Verma, Laxmi Rani, Sweta Kamboj, Rohit Kamboj, Tanu Kamboj, Shailendra Bhatt

Abstract readReview
PubMed Publisher
In one paragraph

Review in Recent patents on nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Pooja MathurDepartment of Pharmacy, School of Medical and Allied Sciences, GD Goenka University, Gurugram, 122103, Haryana, India.
Ravinder VermaDepartment of Pharmaceutical Sciences, Chaudhary Bansi Lal University, Bhiwani (Haryana), 127021, India.ORCID 0000-0003-3397-703X
Laxmi RaniDepartment of Pharmacy, School of Medical and Allied Sciences, GD Goenka University, Gurugram, 122103, Haryana, India.
Sweta KambojGuru Gobind Singh College of Pharmacy, Yamuna Nagar, 135001, Haryana, India.
Rohit KambojGuru Gobind Singh College of Pharmacy, Yamuna Nagar, 135001, Haryana, India.
Tanu KambojGuru Gobind Singh College of Pharmacy, Yamuna Nagar, 135001, Haryana, India.
Shailendra BhattDepartment of Pharmacy, School of Medical and Allied Sciences, GD Goenka University, Gurugram, 122103, Haryana, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Poloxamers, commonly known as Pluronics, are a special family of synthetic tri-block copolymers with a core structure made of hydrophobic poly (propylene oxide) chains sandwiched by two hydrophilic poly (ethylene oxide) chains. It is possible to modify the mechanical, bioactive, and microstructural characteristics of Pluronics to simulate the behavior of different types of tissues. Additionally, they are auspicious drug carriers with the capacity to increase therapeutic agent availability and to design nano-drug formulations for various ailments. The nanoformulation composed of Pluronics is more susceptible to cancer cells due to their amphiphilic nature and feature of selfassembling into micelles. Today's expanding poloxamer research is creating new hopes that increase the possibility of new remedies for a brand-new nanomedicine age treatment. This article provides a concise overview of the classification, grading, and attributes of drug delivery systems (DDSs) as well as the potential for Pluronics to create micro and nanocarriers. We subsequently discuss its utility in drug delivery for cancer, gene therapy, anti-infective therapy, antioxidants, anti-diabetic drugs, anti-HIV, Alzheimer's disease, and antimicrobial drugs. This review also highlighted several patented formulations that contain various grades of Pluronics in one or more different ways..The.recent findings in fundamental research in the field properly demonstrate the strong interest in these novel pharmaceutical strategies.

Indexed as

Drug CarriersNanoparticlesPoloxamerAnimalsColloidsDrug Delivery SystemsHumansMicellesNeoplasmsPatents as TopicColloidsDrug CarriersMicellesPoloxamergene therapymicro and nanocarriersnano-drug formulations.nanomedicinepluronicsPoloxamer

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.